(Q33463751)

27 July 2017

title

Short-course chemotherapy of tuberculosis with largely twice-weekly isoniazid-rifampin (English)

1 reference

27 July 2017

Short-course Chemotherapy for Tuberculosis with Largely Twice-weekly Isoniazid-Rifampin (English)

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

15 May 2023

1 reference

1 reference

0 references

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

15 May 2023

author name string

A. K. Dutt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A446131

2 July 2022

L. Jones

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A446131

2 July 2022

W. W. Stead

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A446131

2 July 2022

language of work or name

English

0 references

publication date

1 April 1979

1 reference

full work available at URL

27 July 2017

https://api.elsevier.com/content/article/PII:S0012369216530633?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

https://api.elsevier.com/content/article/PII:S0012369216530633?httpAccept=text/plain

15 May 2023

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

15 May 2023

1 reference

27 July 2017

volume

75

1 reference

27 July 2017

issue

4

1 reference

27 July 2017

page(s)

441-447

1 reference

Toward shorter-course antituberculosis chemotherapy

27 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

15 May 2023

2

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Rifampicin in treatment of experimental tuberculosis in mice

15 May 2023

4

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Rifampicin in the treatment of experimental tuberculosis in mice: sterilization of tubercle bacilli in the tissues

15 May 2023

5

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results

15 May 2023

9

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Suitability of rifampicin for intermittent administration in the treatment of tuberculosis

15 May 2023

10

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months

15 May 2023

14

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore

15 May 2023

17

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Short course treatment with two drugs, isoniazid plus rifampicin for six months: a controlled clinical trial with two treatment regimens

15 May 2023

18

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland

15 May 2023

20

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services

15 May 2023

29

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Domiciliary drug therapy of pulmonary tuberculosis in a rural population in India

15 May 2023

30

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

The impact of chemotherapy on the care of patients with tuberculosis

15 May 2023

32

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Philip Ellman lecture. The modern management and therapy of pulmonary tuberculosis

15 May 2023

36

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Treatment of tuberculosis by the nonpulmonary physician

15 May 2023

37

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Follow-up of patients with tuberculosis treated in a general hospital program. Treatment largely as outpatients by community physicians

15 May 2023

38

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months

15 May 2023

41

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Clinical studies with a new rifamycin derivative

15 May 2023

43

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Effect of Rifampicin and Isoniazid on Liver Function

15 May 2023

44

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Serum enzyme changes in patients receiving antituberculosis therapy with rifampicin or p-aminosalicylic acid, plus isoniazid and streptomycin

15 May 2023

45

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Adverse reactions to rifampicin in antituberculosis regimens

15 May 2023

47

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Rifampicin-induced immune thrombocytopenia

15 May 2023

48

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin

15 May 2023

49

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Massive haemolysis caused by rifampicin.

15 May 2023

52

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong

15 May 2023

53

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Controlled clinical evaluation of three intermittent regimens employing low-dosage schedules of rifampicin in original treatment of pulmonary tuberculosis. Preliminary data on effectiveness and side effects

15 May 2023

57

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

Intermittent Therapy with Rifampin Once a Week in Advanced Pulmonary Tuberculosis

15 May 2023

58

1 reference

https://api.crossref.org/works/10.1378/CHEST.75.4.441

15 May 2023

Identifiers

1 reference

27 July 2017

1 reference